Forest Stands Tall As Wall Street Chops 15% Off Rx Stocks

Forest's plan to extricate the antidepressant Celexa from a successful co-promotion deal has made the company the unlikely early winner on Wall Street in the bidding war over Warner-Lambert.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet